Analysts’ Viewpoint
Rise in incidence of cancer and growth in investment in cancer research are significant factors fueling cancer profiling market expansion. Increase in demand for consumable products is also anticipated to drive market progress in the near future. Growth in preference for personalized medicine is expected to create lucrative opportunities for market players during the forecast period.
The market for cancer profiling is growing rapidly, driven by advances in technology. Advancements in molecular profiling techniques are providing new opportunities for personalized cancer treatment. Some of the key players are focusing on growth strategies such as mergers & acquisitions and new product launches. They are also increasingly investing in R&D activities to expand their product portfolio.
Cancer profiling is the process of analyzing the molecular and genetic characteristics of cancer. Through this analysis, healthcare providers can develop personalized treatment plans to improve outcomes and minimize side effects.
Cancer profiling involves analyzing cancer cells to identify specific mutations and pathways that are driving tumor growth. It can be used to develop targeted therapies that are more effective and carry fewer side effects than traditional chemotherapy. Tumor profiling can be used to identify the most effective treatment options for individual patients, based on their unique genetic profile.
The market for cancer profiling is primarily driven by the increase in cancer cases across the globe. Lung cancer, colorectal cancer, breast cancer, and prostate cancer are some of the prominent cancer types affecting the global population.
Incidence and mortality of cancer are increasing consistently across the globe. This can be ascribed to the growth in aging population as well as changes in prevalence and distribution of key risk factors for cancer, some of which are connected to socioeconomic development.
More precise and effective cancer diagnostic techniques are required to locate and categorize cancer cells. The cancer profiling market size is expected to rise significantly in the next few years due to the increase in research and development activities in the area of cancer profiling.
Various organizations in developed and developing countries are investing significantly in cancer research to explore new treatments, improve patient outcomes, and find a cure for the disease. This can be ascribed to the rise in burden of cancer on individuals, families, and societies across the globe.
In April 2023, a team of researchers from the Leiden University Medical Center (LUMC) received a Euro 3.0 Mn grant on behalf of the Drug Rediscovery Protocol team to tailor cancer treatments based on the genetic makeup of the tumor.
Based on product, the consumables segment accounted for major market share in 2022 due to the increase in usage of consumables in day-to-day operations in cancer profiling labs.
Consumable products that are used in cancer profiling include a wide range of reagents and assay components such as antibodies, buffers, enzymes, and probes. These products are used in various cancer profiling methods, such as genomic profiling, proteomic profiling, and imaging techniques, to analyze the molecular characteristics of cancer cells.
Consumable products are required for every step of the cancer profiling process, from sample preparation to data analysis. According to a cancer profiling market research report, demand for consumable products is estimated to rise significantly in the near future.
Polymerase chain reaction (PCR) is a leading technology for cancer profiling due to its high sensitivity and specificity in detecting specific DNA sequences. PCR is a widely used molecular biology technique that amplifies a specific segment of DNA, allowing for the detection and quantification of a specific gene or mutation associated with cancer.
Polymerase chain reaction can be used to detect specific mutations or alterations in cancer cells, providing valuable information for diagnosis, prognosis, and treatment. For instance, PCR can be used to detect specific genetic mutations in tumor DNA that are associated with specific cancer types, such as mutations in the KRAS gene that are commonly found in pancreatic cancer. Rise in adoption of PCR technology is contributing to the market growth.
As per cancer profiling market analysis, rise in prevalence of lung cancer is a key factor boosting industry dynamics. Lung cancer is the second most common cancer worldwide. It is the most common cancer in men and the second most common cancer in women.
Lung cancer is the primary cause of cancer-related deaths worldwide. Incidence of this type of cancer is expected to continue to rise in the next few years. However, development of new treatments, such as immunotherapies and targeted therapies, has improved the survival rate and management of lung cancer patients.
Increase in usage of screening and early detection methods are likely to boost cancer profiling market demand during the forecast period.
According to the cancer profiling market report, North America is projected to dominate the global landscape during the forecast period.
Cancer incidences are rising significantly in North America owing to growth in aging population, high rate of obesity, and environmental factors. The region is likely to account for significant cancer profiling market share in the near future.
According to the cancer profiling market research, breast cancer, lung cancer, prostate cancer, and colorectal cancer are the most common types of cancer in North America.
Abbott Laboratories, Agilent Technologies Inc., F. Hoffmann-La Roche Ltd, HTG Molecular Diagnostics, Inc., Illumina, Inc., PerkinElmer Inc., QIAGEN N.V., Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific Inc., Hologic, Inc., and Guardant Health are some of the prominent players in the global market.
Each of these players has been profiled in the cancer profiling market forecast report based on parameters such as product portfolio, recent developments, financial overview, company overview, business strategies, and business segments. Leading cancer profiling companies are engaged in strategic acquisitions and partnerships to strengthen their market position.
| Attribute | Detail |
|---|---|
|
Market Value in 2022 |
US$ 13.4 Bn |
|
Forecast Value in 2031 |
More than US$ 31.4 Bn |
|
Growth Rate (CAGR) |
10.3% |
|
Forecast Period |
2023-2031 |
|
Historical Data Available for |
2017-2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
It was valued at US$ 13.4 Bn in 2022
It is projected to reach more than US$ 31.4 Bn by 2031
The CAGR is anticipated to be 10.3% from 2023 to 2031
Increase in prevalence of cancer and growth in investment in cancer research
The consumables product segment accounted for more than 60.0% share in 2022
North America is likely to constitute the largest share from 2023 to 2031
Abbott Laboratories, Agilent Technologies Inc., F. Hoffmann-La Roche Ltd, HTG Molecular Diagnostics, Inc., Illumina, Inc., PerkinElmer Inc., QIAGEN N.V., Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific Inc., Hologic, Inc., and Guardant Health
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cancer Profiling Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cancer Profiling Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Regulatory Scenario for Cancer Profiling
5.2. Cancer Epidemiology, by Region
5.3. Technological Advancements in Cancer Profiling Technology
5.4. COVID-19 Impact on the Industry
6. Global Cancer Profiling Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product, 2017-2031
6.3.1. Instruments
6.3.1.1. Immunohistochemistry Analyzers
6.3.1.2. In Situ Hybridization Instruments
6.3.1.3. Polymerase Chain Reaction Instruments
6.3.1.4. DNA Sequencers
6.3.1.5. Fragment Analyzers
6.3.2. Consumables
6.3.2.1. Reagents & Kits
6.3.2.2. Others
6.4. Market Attractiveness Analysis, by Product
7. Global Cancer Profiling Market Analysis and Forecast, by Technology
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Technology, 2017-2031
7.3.1. Immunohistochemistry
7.3.2. Next Generation Sequencing
7.3.3. Polymerase Chain Reaction
7.3.4. In Situ Hybridization
7.3.5. Microarrays
7.3.6. Fragment Analysis
7.3.7. Others
7.4. Market Attractiveness Analysis, by Technology
8. Global Cancer Profiling Market Analysis and Forecast, by Cancer Type
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Cancer Type, 2017-2031
8.3.1. Breast Cancer
8.3.2. Lung Cancer
8.3.3. Colorectal Cancer
8.3.4. Prostate Cancer
8.3.5. Prostate Cancer
8.3.6. Melanoma
8.3.7. Others
8.4. Market Attractiveness Analysis, by Cancer Type
9. Global Cancer Profiling Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2017-2031
9.3.1. Hospitals
9.3.2. Diagnostic Centers
9.3.3. Cancer Research Institutes
9.3.4. Others
9.4. Market Attractiveness Analysis, by End-user
10. Global Cancer Profiling Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017-2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Country/Region
11. North America Cancer Profiling Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017-2031
11.2.1. Instruments
11.2.1.1. Immunohistochemistry Analyzers
11.2.1.2. In Situ Hybridization Instruments
11.2.1.3. Polymerase Chain Reaction Instruments
11.2.1.4. DNA Sequencers
11.2.1.5. Fragment Analyzers
11.2.2. Consumables
11.2.2.1. Reagents & Kits
11.2.2.2. Others
11.3. Market Value Forecast, by Technology, 2017-2031
11.3.1. Immunohistochemistry
11.3.2. Next Generation Sequencing
11.3.3. Polymerase Chain Reaction
11.3.4. In Situ Hybridization
11.3.5. Microarrays
11.3.6. Fragment Analysis
11.3.7. Others
11.4. Market Value Forecast, by Cancer Type, 2017-2031
11.4.1. Breast Cancer
11.4.2. Lung Cancer
11.4.3. Colorectal Cancer
11.4.4. Prostate Cancer
11.4.5. Prostate Cancer
11.4.6. Melanoma
11.4.7. Others
11.5. Market Value Forecast, by End-user, 2017-2031
11.5.1. Hospitals
11.5.2. Diagnostic Centers
11.5.3. Cancer Research Institutes
11.5.4. Others
11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Product
11.7.2. By Technology
11.7.3. By Cancer Type
11.7.4. By End-user
11.7.5. By Country
12. Europe Cancer Profiling Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017-2031
12.2.1. Instruments
12.2.1.1. Immunohistochemistry Analyzers
12.2.1.2. In Situ Hybridization Instruments
12.2.1.3. Polymerase Chain Reaction Instruments
12.2.1.4. DNA Sequencers
12.2.1.5. Fragment Analyzers
12.2.2. Consumables
12.2.2.1. Reagents & Kits
12.2.2.2. Others
12.3. Market Value Forecast, by Technology, 2017-2031
12.3.1. Immunohistochemistry
12.3.2. Next Generation Sequencing
12.3.3. Polymerase Chain Reaction
12.3.4. In Situ Hybridization
12.3.5. Microarrays
12.3.6. Fragment Analysis
12.3.7. Others
12.4. Market Value Forecast, by Cancer Type, 2017-2031
12.4.1. Breast Cancer
12.4.2. Lung Cancer
12.4.3. Colorectal Cancer
12.4.4. Prostate Cancer
12.4.5. Prostate Cancer
12.4.6. Melanoma
12.4.7. Others
12.5. Market Value Forecast, by End-user, 2017-2031
12.5.1. Hospitals
12.5.2. Diagnostic Centers
12.5.3. Cancer Research Institutes
12.5.4. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Product
12.7.2. By Technology
12.7.3. By Cancer Type
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Cancer Profiling Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017-2031
13.2.1. Instruments
13.2.1.1. Immunohistochemistry Analyzers
13.2.1.2. In Situ Hybridization Instruments
13.2.1.3. Polymerase Chain Reaction Instruments
13.2.1.4. DNA Sequencers
13.2.1.5. Fragment Analyzers
13.2.2. Consumables
13.2.2.1. Reagents & Kits
13.2.2.2. Others
13.3. Market Value Forecast, by Technology, 2017-2031
13.3.1. Immunohistochemistry
13.3.2. Next Generation Sequencing
13.3.3. Polymerase Chain Reaction
13.3.4. In Situ Hybridization
13.3.5. Microarrays
13.3.6. Fragment Analysis
13.3.7. Others
13.4. Market Value Forecast, by Cancer Type, 2017-2031
13.4.1. Breast Cancer
13.4.2. Lung Cancer
13.4.3. Colorectal Cancer
13.4.4. Prostate Cancer
13.4.5. Prostate Cancer
13.4.6. Melanoma
13.4.7. Others
13.5. Market Value Forecast, by End-user, 2017-2031
13.5.1. Hospitals
13.5.2. Diagnostic Centers
13.5.3. Cancer Research Institutes
13.5.4. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Product
13.7.2. By Technology
13.7.3. By Cancer Type
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Cancer Profiling Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2017-2031
14.2.1. Instruments
14.2.1.1. Immunohistochemistry Analyzers
14.2.1.2. In Situ Hybridization Instruments
14.2.1.3. Polymerase Chain Reaction Instruments
14.2.1.4. DNA Sequencers
14.2.1.5. Fragment Analyzers
14.2.2. Consumables
14.2.2.1. Reagents & Kits
14.2.2.2. Others
14.3. Market Value Forecast, by Technology, 2017-2031
14.3.1. Immunohistochemistry
14.3.2. Next Generation Sequencing
14.3.3. Polymerase Chain Reaction
14.3.4. In Situ Hybridization
14.3.5. Microarrays
14.3.6. Fragment Analysis
14.3.7. Others
14.4. Market Value Forecast, by Cancer Type, 2017-2031
14.4.1. Breast Cancer
14.4.2. Lung Cancer
14.4.3. Colorectal Cancer
14.4.4. Prostate Cancer
14.4.5. Prostate Cancer
14.4.6. Melanoma
14.4.7. Others
14.5. Market Value Forecast, by End-user, 2017-2031
14.5.1. Hospitals
14.5.2. Diagnostic Centers
14.5.3. Cancer Research Institutes
14.5.4. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Product
14.7.2. By Technology
14.7.3. By Cancer Type
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Cancer Profiling Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Product, 2017-2031
15.2.1. Instruments
15.2.1.1. Immunohistochemistry Analyzers
15.2.1.2. In Situ Hybridization Instruments
15.2.1.3. Polymerase Chain Reaction Instruments
15.2.1.4. DNA Sequencers
15.2.1.5. Fragment Analyzers
15.2.2. Consumables
15.2.2.1. Reagents & Kits
15.2.2.2. Others
15.3. Market Value Forecast, by Technology, 2017-2031
15.3.1. Immunohistochemistry
15.3.2. Next Generation Sequencing
15.3.3. Polymerase Chain Reaction
15.3.4. In Situ Hybridization
15.3.5. Microarrays
15.3.6. Fragment Analysis
15.3.7. Others
15.4. Market Value Forecast, by Cancer Type, 2017-2031
15.4.1. Breast Cancer
15.4.2. Lung Cancer
15.4.3. Colorectal Cancer
15.4.4. Prostate Cancer
15.4.5. Prostate Cancer
15.4.6. Melanoma
15.4.7. Others
15.5. Market Value Forecast, by End-user, 2017-2031
15.5.1. Hospitals
15.5.2. Diagnostic Centers
15.5.3. Cancer Research Institutes
15.5.4. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Product
15.7.2. By Technology
15.7.3. By Cancer Type
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
16.3.1. Abbott Laboratories
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Agilent Technologies Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. F. Hoffmann-La Roche Ltd
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. HTG Molecular Diagnostics, Inc.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Illumina, Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. PerkinElmer Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. QIAGEN N.V.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Siemens Healthineers
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Sysmex Corporation
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Thermo Fisher Scientific Inc.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. Hologic, Inc.
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview
16.3.12. Guardant Health
16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.12.2. Product Portfolio
16.3.12.3. Financial Overview
16.3.12.4. SWOT Analysis
16.3.12.5. Strategic Overview
List of Tables
Table 01: Global Cancer Profiling Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 02: Global Cancer Profiling Market Value (US$ Mn) Forecast, by Instruments, 2017-2031
Table 03: Global Cancer Profiling Market Value (US$ Mn) Forecast, by Consumables, 2017-2031
Table 03: Global Cancer Profiling Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 04: Global Cancer Profiling Market Value (US$ Mn) Forecast, by Cancer Type, 2017-2031
Table 05: Global Cancer Profiling Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 06: Global Cancer Profiling Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 07: North America Cancer Profiling Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 08: North America Cancer Profiling Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 09: North America Cancer Profiling Market Value (US$ Mn) Forecast, by Instruments, 2017-2031
Table 10: North America Cancer Profiling Market Value (US$ Mn) Forecast, by Consumables, 2017-2031
Table 11: North America Cancer Profiling Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 12: North America Cancer Profiling Market Value (US$ Mn) Forecast, by Cancer Type, 2017-2031
Table 13: North America Cancer Profiling Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 14: Europe Cancer Profiling Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 15: Europe Cancer Profiling Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 16: Europe Cancer Profiling Market Value (US$ Mn) Forecast, by Instruments, 2017-2031
Table 17: Europe Cancer Profiling Market Value (US$ Mn) Forecast, by Consumables, 2017-2031
Table 18: Europe Cancer Profiling Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 19: Europe Cancer Profiling Market Value (US$ Mn) Forecast, by Cancer Type, 2017-2031
Table 20: Europe Cancer Profiling Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 21: Asia Pacific Cancer Profiling Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Asia Pacific Cancer Profiling Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 23: Asia Pacific Cancer Profiling Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 24: Asia Pacific Cancer Profiling Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 25: Asia Pacific Cancer Profiling Market Value (US$ Mn) Forecast, by Therapy, 2017-2031
Table 26: Asia Pacific Cancer Profiling Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 27: Latin America Cancer Profiling Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 28: Latin America Cancer Profiling Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 29: Latin America Cancer Profiling Market Value (US$ Mn) Forecast, by Instruments 2017-2031
Table 30: Latin America Cancer Profiling Market Value (US$ Mn) Forecast, by Consumables, 2017-2031
Table 31: Latin America Cancer Profiling Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 32: Latin America Cancer Profiling Market Value (US$ Mn) Forecast, by Cancer Type, 2017-2031
Table 34: Latin America Cancer Profiling Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 35: Middle East & Africa Cancer Profiling Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 36: Middle East & Africa Cancer Profiling Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 37: Middle East & Africa Cancer Profiling Market Value (US$ Mn) Forecast, by Instruments, 2017-2031
Table 38: Middle East & Africa Cancer Profiling Market Value (US$ Mn) Forecast, by Consumables, 2017-2031
Table 39: Middle East & Africa Cancer Profiling Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 40: Middle East & Africa Cancer Profiling Market Value (US$ Mn) Forecast, by Cancer Type, 2017-2031
Table 41: Middle East & Africa Cancer Profiling Market Value (US$ Mn) Forecast, by End-user, 2017-2031
List of Figures
Figure 01: Global Cancer Profiling Market Value Share Analysis, by Product, 2021 and 2031
Figure 02: Global Cancer Profiling Market Attractiveness Analysis, Product, 2022-2031
Figure 03: Global Cancer Profiling Market (US$ Mn), by Instrument, 2017-2031
Figure 04: Global Cancer Profiling Market (US$ Mn), by Immunohistochemistry Analyzers, 2017-2031
Figure 05: Global Cancer Profiling Market (US$ Mn), by In Situ Hybridization Instruments, 2017-2031
Figure 06: Global Cancer Profiling Market (US$ Mn), by Polymerase Chain Reaction Instruments, 2017-2031
Figure 07: Global Cancer Profiling Market (US$ Mn), by DNA Sequencers, 2017-2031
Figure 08: Global Cancer Profiling Market (US$ Mn), by Fragment Analyzers, 2017-2031
Figure 09: Global Cancer Profiling Market Value Share Analysis, by Technology, 2021 and 2031
Figure 10: Global Cancer Profiling Market Attractiveness Analysis, Technology, 2022-2031
Figure 11: Global Cancer Profiling Market (US$ Mn), by Immunohistochemistry, 2017-2031
Figure 12: Global Cancer Profiling Market (US$ Mn), by Next Generation Sequencing, 2017-2031
Figure 13: Global Cancer Profiling Market (US$ Mn), by Polymerase Chain Reaction, 2017-2031
Figure 14: Global Cancer Profiling Market (US$ Mn), by In Situ Hybridization, 2017-2031
Figure 15: Global Cancer Profiling Market (US$ Mn), by Microarrays, 2017-2031
Figure 16: Global Cancer Profiling Market (US$ Mn), by Fragment Analysis, 2017-2031
Figure 17: Global Cancer Profiling Market (US$ Mn), by Others, 2017-2031
Figure 18: Global Cancer Profiling Market Value Share Analysis, by Cancer Type 2021 and 2031
Figure 19: Global Cancer Profiling Market Attractiveness Analysis, Cancer Type, 2022-2031
Figure 20: Global Cancer Profiling Market (US$ Mn), by Breast Cancer, 2017-2031
Figure 21: Global Cancer Profiling Market (US$ Mn), by Lung Cancer, 2017-2031
Figure 22: Global Cancer Profiling Market (US$ Mn), by Colorectal Cancer, 2017-2031
Figure 23: Global Cancer Profiling Market (US$ Mn), by Prostate Cancer, 2017-2031
Figure 24: Global Cancer Profiling Market (US$ Mn), by Melanoma, 2017-2031
Figure 25: Global Cancer Profiling Market (US$ Mn), by Others, 2017-2031
Figure 26: Global Cancer Profiling Market Value Share Analysis, by End-user, 2021 and 2031
Figure 27: Global Cancer Profiling Market Attractiveness Analysis, End-user, 2022-2031
Figure 28: Global Cancer Profiling Market (US$ Mn), by Hospitals, 2017-2031
Figure 29: Global Cancer Profiling Market (US$ Mn), by Diagnostic Centers, 2017-2031
Figure 30: Global Cancer Profiling Market (US$ Mn), by Cancer Research Institutes, 2017-2031
Figure 31: Global Cancer Profiling Market (US$ Mn), by Others, 2017-2031
Figure 32: Global Cancer Profiling Market Attractiveness Analysis, by Region, 2022-2031
Figure 33: Global Cancer Profiling Market Value Share Analysis, by Region, 2021 and 2031
Figure 34: Global Cancer Profiling Market Attractiveness Analysis, by Region, 2022-2031
Figure 35: North America Cancer Profiling Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 36: North America Cancer Profiling Market Value Share Analysis, by Country, 2021 and 2031
Figure 37: North America Cancer Profiling Market Attractiveness, by Country, 2022-2031
Figure 38: North America Cancer Profiling Market Value Share Analysis, by Product, 2021 and 2031
Figure 39: North America Cancer Profiling Market Attractiveness, by Product, 2022-2031
Figure 40: North America Cancer Profiling Market Value Share Analysis, by Technology, 2021 and 2031
Figure 41: North America Cancer Profiling Market Attractiveness, by Technology, 2022-2031
Figure 42: North America Cancer Profiling Market Value Share Analysis, by Cancer Type, 2021 and 2031
Figure 43: North America Cancer Profiling Market Attractiveness, by Cancer Type, 2022-2031
Figure 44: North America Cancer Profiling Market Value Share Analysis, by End-user, 2021 and 2031
Figure 45: North America Cancer Profiling Market Attractiveness, by End-user, 2022-2031
Figure 46: Europe Cancer Profiling Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 47: Europe Cancer Profiling Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 48: Europe Cancer Profiling Market Attractiveness, by Country/Sub-region, 2022-2031
Figure 49: Europe Cancer Profiling Market Value Share Analysis, by Product, 2021 and 2031
Figure 50: Europe Cancer Profiling Market Attractiveness, by Product, 2022-2031
Figure 51: Europe Cancer Profiling Market Value Share Analysis, by Technology, 2021 and 2031
Figure 52: Europe Cancer Profiling Market Attractiveness, by Technology, 2022-2031
Figure 53: Europe Cancer Profiling Market Value Share Analysis, by Cancer Type, 2021 and 2031
Figure 54: Europe Cancer Profiling Market Attractiveness, by Cancer Type, 2022-2031
Figure 55: Europe Cancer Profiling Market Value Share Analysis, by End-user, 2021 and 2031
Figure 56: Europe Cancer Profiling Market Attractiveness, by End-user, 2022-2031
Figure 57: Asia Pacific Cancer Profiling Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 58: Asia Pacific Cancer Profiling Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 59: Asia Pacific Cancer Profiling Market Attractiveness, by Country/Sub-region, 2022-2031
Figure 60: Asia Pacific Cancer Profiling Market Value Share Analysis, by Product, 2021 and 2031
Figure 61: Asia Pacific Cancer Profiling Market Attractiveness, by Product, 2022-2031
Figure 62: Asia Pacific Cancer Profiling Market Value Share Analysis, by Technology, 2021 and 2031
Figure 63: Asia Pacific Cancer Profiling Market Attractiveness, by Technology, 2022-2031
Figure 64: Asia Pacific Cancer Profiling Market Value Share Analysis, by Cancer Type, 2021 and 2031
Figure 65: Asia Pacific Cancer Profiling Market Attractiveness, by Cancer Type, 2022-2031
Figure 66: Asia Pacific Cancer Profiling Market Value Share Analysis, by End-user, 2021 and 2031
Figure 67: Asia Pacific Cancer Profiling Market Attractiveness, by End-user, 2022-2031
Figure 68: Latin America Cancer Profiling Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 69: Latin America Cancer Profiling Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 70: Latin America Cancer Profiling Market Attractiveness, by Country/Sub-region, 2022-2031
Figure 71: Latin America Cancer Profiling Market Value Share Analysis, by Product, 2021 and 2031
Figure 72: Latin America Cancer Profiling Market Attractiveness, by Product, 2022-2031
Figure 73: Latin America Cancer Profiling Market Value Share Analysis, by Technology, 2021 and 2031
Figure 74: Latin America Cancer Profiling Market Attractiveness, by Technology, 2022-2031
Figure 75: Latin America Cancer Profiling Market Value Share Analysis, by Cancer Type, 2021 and 2031
Figure 76: Latin America Cancer Profiling Market Attractiveness, by Cancer Type, 2022-2031
Figure 77: Latin America Cancer Profiling Market Value Share Analysis, by End-user, 2021 and 2031
Figure 78: Latin America Cancer Profiling Market Attractiveness, by End-user, 2022-2031
Figure 79: Middle East & Africa Cancer Profiling Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 80: Middle East & Africa Cancer Profiling Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 81: Middle East & Africa Cancer Profiling Market Attractiveness, by Country/Sub-region, 2022-2031
Figure 82: Middle East & Africa Cancer Profiling Market Value Share Analysis, by Product, 2021 and 2031
Figure 83: Middle East & Africa Cancer Profiling Market Attractiveness, by Product, 2022-2031
Figure 84: Middle East & Africa Cancer Profiling Market Value Share Analysis, by Technology, 2021 and 2031
Figure 85: Middle East & Africa Cancer Profiling Market Attractiveness, by Technology, 2022-2031
Figure 86: Middle East & Africa Cancer Profiling Market Value Share Analysis, by Cancer Type, 2021 and 2031
Figure 87: Middle East & Africa Cancer Profiling Market Attractiveness, by Cancer Type, 2022-2031
Figure 88: Middle East & Africa Cancer Profiling Market Value Share Analysis, by End-user, 2021 and 2031
Figure 89: Middle East & Africa Cancer Profiling Market Attractiveness, by End-user, 2022-2031
Figure 90: Global Cancer Profiling Market Share Analysis, by Company 2022
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Cancer Profiling Market
